Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Merelbeke – page 74

1 667 clinical trials in Merelbeke, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Merelbeke at a glance
1 667
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 667 trials in Merelbeke

Open in trial search

Fungal infection

Not recruiting

Study on Rezafungin to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fluconazole
  • Sponsor:Mundipharma Research Limited

Study of Tepotinib and Osimertinib for Patients with Advanced or Metastatic Lung Cancer Resistant to Osimertinib Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Merck Healthcare KGaA

Study of Tepotinib for Patients with Advanced Lung Cancer with MET Exon 14 Skipping Alterations or MET Amplification

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tepotinib
  • Sponsor:Merck Healthcare KGaA

Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Argenx

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with a Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of 19CP02 for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:19Cp02
  • Sponsor:Lakefront Biotherapeutics

IgA nephropathy

Not recruiting

Study on the Effects of Atacicept in Adults with IgA Nephropathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Crohn's disease

Not recruiting

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Study on Langerhans Cell Histiocytosis Treatment in Children and Adolescents Using Cladribine, Prednisolone, and Cytarabine

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Alemtuzumab
  • Sponsor:St. Anna Childrens Cancer Research Institute GmbH

Study on Allogeneic Stem Cell Transplantation for Children and Adolescents with Acute Lymphoblastic Leukemia Using Etoposide, Treosulfan, and Thiotepa

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:St. Anna Childrens Cancer Research Institute GmbH

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Merelbeke

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) medication management in patients with chronic digestive conditions. This research explores optimal approaches for medication reduction in cases where long-term use may not be indicated.

  • Functional Dyspepsia
  • Gastroesophageal Reflux
  • Chronic Heartburn

The study evaluates different deprescribing strategies, including on-demand PPI use and alternative treatments with alginate formulations, aiming to improve patient care in primary healthcare settings.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.